Neurocrine Biosciences | NBIX - Interest Expense On Debt


Neurocrine Biosciences reported $1.1M in Interest Expense on Debt for its fiscal quarter ending in March of 2024.





Interest Expense On Debt Change Date
AbbVie USD 740M 40M Jun/2025
Acadia Pharmaceuticals USD 0 4.12M Sep/2024
Agios Pharmaceuticals USD 1.39B 85.53M Sep/2025
ALKERMES USD 4.65M 1.35M Dec/2024
Alnylam Pharmaceuticals USD 44.4M 4.15M Sep/2025
Amgen USD 685M 9M Sep/2025
Biogen USD 72.6M 12.6M Jun/2025
BioMarin Pharmaceutical USD 2.58M 100K Sep/2025
Cytokinetics USD 26.32M 2.06M Sep/2025
Dynavax Technologies USD 1.64M 2K Sep/2025
Exelixis USD 23.4M 3.9M Sep/2023
Gilead Sciences USD 254M 6M Jun/2025
Halozyme Therapeutics USD 4.3M 98K Sep/2025
Incyte USD 592K 2K Sep/2025
Ionis Pharmaceuticals USD 18M 1000K Sep/2025
Neurocrine Biosciences USD 1.1M 0 Mar/2024
Pfizer USD 652M 2M Sep/2025
Prothena USD 352.63M 46.44M Sep/2025
Regeneron Pharmaceuticals USD 12.2M 7.1M Dec/2025
Repligen USD 5.41M 60K Sep/2025
Sarepta Therapeutics USD 7.56M 2.33M Sep/2025
Teva Pharmaceutical Industries USD 220M 17M Dec/2025
Ultragenyx Pharmaceutical USD 14.15M 108K Sep/2025
Vertex Pharmaceuticals USD 3.3M 400K Sep/2025